Lack of Effect of Cyclophosphamide on the Immunogenicity of a Melanoma Antigen Vaccine

Ruth Oratz; Margaret Dugan; Daniel F. Roses; Matthew N. Harris; James L. Speyer; Howard Hochster; Jolie Weissman; Mila Henn; Jean Claude Bystryn

Lack of Effect of Cyclophosphamide on the Immunogenicity of a Melanoma Antigen Vaccine

Ruth Oratz, Margaret Dugan, Daniel F. Roses, Matthew N. Harris, James L. Speyer, Howard Hochster, Jolie Weissman, Mila Henn, Jean Claude Bystryn

Research output: Contribution to journal › Article › peer-review

20 Scopus citations

Abstract

Melanoma antigen vaccines are a conceptually attractive approach to prevent or delay disease recurrence in patients with surgically resected malignant melanoma. However, the immunogenicity of current vaccines is relatively low. Cyclophosphamide, when given in low doses prior to antigen exposure, is an immunomodulator which has been shown to enhance both humoral and cellular antitumor responses in animals and humans. We conducted a prospective, randomized, clinical trial to study whether pretreatment with Cyclophosphamide augments the immunoge nicity of a polyvalent, allogeneic, melanoma antigen vaccine in patients with melanoma and low tumor burden. Forty-five patients with resected stage II melanoma (regional mã

Original language	American English
Pages (from-to)	3643-3647
Number of pages	5
Journal	Cancer Research
Volume	51
Issue number	14
State	Published - Jul 15 1991
Externally published	Yes

ASJC Scopus subject areas

Oncology
Cancer Research

Cite this

@article{1de1d82ac88d4b49b5f289c406474d63,

title = "Lack of Effect of Cyclophosphamide on the Immunogenicity of a Melanoma Antigen Vaccine",

abstract = "Melanoma antigen vaccines are a conceptually attractive approach to prevent or delay disease recurrence in patients with surgically resected malignant melanoma. However, the immunogenicity of current vaccines is relatively low. Cyclophosphamide, when given in low doses prior to antigen exposure, is an immunomodulator which has been shown to enhance both humoral and cellular antitumor responses in animals and humans. We conducted a prospective, randomized, clinical trial to study whether pretreatment with Cyclophosphamide augments the immunoge nicity of a polyvalent, allogeneic, melanoma antigen vaccine in patients with melanoma and low tumor burden. Forty-five patients with resected stage II melanoma (regional m{\~a}",

author = "Ruth Oratz and Margaret Dugan and Roses, {Daniel F.} and Harris, {Matthew N.} and Speyer, {James L.} and Howard Hochster and Jolie Weissman and Mila Henn and Bystryn, {Jean Claude}",

year = "1991",

month = jul,

day = "15",

language = "American English",

volume = "51",

pages = "3643--3647",

journal = "Cancer Research",

issn = "0008-5472",

publisher = "American Association for Cancer Research Inc.",

number = "14",

}

TY - JOUR

T1 - Lack of Effect of Cyclophosphamide on the Immunogenicity of a Melanoma Antigen Vaccine

AU - Oratz, Ruth

AU - Dugan, Margaret

AU - Roses, Daniel F.

AU - Harris, Matthew N.

AU - Speyer, James L.

AU - Hochster, Howard

AU - Weissman, Jolie

AU - Henn, Mila

AU - Bystryn, Jean Claude

PY - 1991/7/15

Y1 - 1991/7/15

N2 - Melanoma antigen vaccines are a conceptually attractive approach to prevent or delay disease recurrence in patients with surgically resected malignant melanoma. However, the immunogenicity of current vaccines is relatively low. Cyclophosphamide, when given in low doses prior to antigen exposure, is an immunomodulator which has been shown to enhance both humoral and cellular antitumor responses in animals and humans. We conducted a prospective, randomized, clinical trial to study whether pretreatment with Cyclophosphamide augments the immunoge nicity of a polyvalent, allogeneic, melanoma antigen vaccine in patients with melanoma and low tumor burden. Forty-five patients with resected stage II melanoma (regional mã

AB - Melanoma antigen vaccines are a conceptually attractive approach to prevent or delay disease recurrence in patients with surgically resected malignant melanoma. However, the immunogenicity of current vaccines is relatively low. Cyclophosphamide, when given in low doses prior to antigen exposure, is an immunomodulator which has been shown to enhance both humoral and cellular antitumor responses in animals and humans. We conducted a prospective, randomized, clinical trial to study whether pretreatment with Cyclophosphamide augments the immunoge nicity of a polyvalent, allogeneic, melanoma antigen vaccine in patients with melanoma and low tumor burden. Forty-five patients with resected stage II melanoma (regional mã

UR - http://www.scopus.com/inward/record.url?scp=0025737526&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025737526&partnerID=8YFLogxK

M3 - Article

C2 - 2065322

SN - 0008-5472

VL - 51

SP - 3643

EP - 3647

JO - Cancer Research

JF - Cancer Research

IS - 14

ER -

Lack of Effect of Cyclophosphamide on the Immunogenicity of a Melanoma Antigen Vaccine

Abstract

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this